AGIO vs IONS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AGIO Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agios Pharmaceuticals, Inc. (AGIO) driven by superior Valuation, Momentum & Technical, Options & Structure while IONS counters with relative strength in Growth & Margin. Fundamentally, AGIO trades at 2.5x Forward P/E with -297.7% operating margin (+330.0% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, AGIO sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AGIO | IONS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $4.7B | Larger Scale | IONS |
| Trailing P/E Ratio Valuation | 2.5x | 90.9x | Lower Multiple | AGIO |
| Forward P/E Ratio Valuation | 2.5x | 90.9x | Lower Multiple | AGIO |
| Revenue Growth (YoY) Growth | +330.0% | +54.9% | Higher Growth | AGIO |
| Operating Margin (TTM) Profitability | -297.7% | -58.8% | Higher Margin | IONS |
| Net Profit Margin Profitability | -264.8% | -56.9% | Higher Margin | IONS |
| Return on Equity (ROE) Capital Efficiency | -33.0% | -108.0% | Higher ROE | AGIO |
| 52-Week Range Position Momentum | 34% ($22โ$46) | 2% ($27โ$87) | Stronger Trend | AGIO |
| Beta / 30D Volatility Risk Regime | 1.12ฮฒ ยท 85% Vol | 0.18ฮฒ ยท 86% Vol | Lower Realized Risk | AGIO |
| Unified Institutional Score Composite Signal | 55.9 / 100 (HOLD) | 63.9 / 100 (BUY) | Higher Composite | IONS |